COMPOSITIONS COMPRISING ALKYLDIMONIUM HYDROXYPROPYL ALKYLGLUCOSIDES
A pharmaceutical formulation for topical, ophthalmic or nasal administration comprising one or more alkyldimonium hydroxypropyl alkylglucosides of general formula I or general formula II and a pharmaceutical active, wherein R is a straight or branched C 8 -C 24 alkyl; A is —CH 2 CH(OH)CH 2 N + (CH 3 ) 2 R 1 X − , wherein R 1 is a C 8 -C 24 alkyl and X − is a common counteranion, n is an average value from 1 to 6 and m is an average value from 1 to 2
1 . A formulation comprising one or more alkyldimonium hydroxypropyl alkylglucosides of general formula I or general formula II and a pharmaceutical active,
wherein R is a straight or branched C 8 -C 24 alkyl;
A is —CH 2 CH(OH)CH 2 N + (CH 3 ) 2 R 1 X − , wherein R 1 is a C 8 -C 24 alkyl and X − is a common counteranion, and a n is an average value from 1 to 6 and m is an average value from 1 to 2, wherein the formulation is a pharmaceutical formulation for topical, ophthalmic or nasal administration.
2 . The formulation of claim 1 wherein the alkyldimonium hydroxypropyl alkylglucoside of general formula I is selected from the group consisting of
stearyldimonium hydroxypropyl laurylglucosides chloride,
stearyldimonium hydroxypropyl laurylglucosides chloride,
stearyldimonium hydroxypropyl decylglucosides chloride,
lauryldimonium hydroxypropyl laurylglucosides chloride,
lauryldimonium hydroxypropyl decylglucosides chloride and
trimonium hydroxypropyl cocoglucosides chloride.
3 . The formulation of claim 1 wherein the alkyldimonium hydroxypropyl alkylglucoside of general formula II is selected from the group consisting of
poly(stearyldimonium hydroxypropyl laurylglucosides chloride,
poly(stearyldimonium hydroxypropyl decylglucosides chloride,
poly(lauryldimonium hydroxypropyl laurylglucosides chloride,
poly(lauryldimonium hydroxypropyl decylglucosides chloride,
poly(trimonium hydroxypropyl laurylglucosides chloride and
poly(trimonium hydroxypropyl decylglucosides chloride.
4 . The formulation of claim 1 wherein the alkyldimonium hydroxypropyl alkylglucoside of general formula I or general formula II is present in the formulation from 0.001% to 0.1% by weight.
5 . The formulation of claim 4 wherein the alkyldimonium hydroxypropyl alkylglucoside of general formula I or general formula II is present in the formulation from 0.003% to 0.05% by weight.
6 . The formulation of claim 1 wherein the one or more alkyldimonium hydroxypropyl alkylglucoside includes stearyldimonium hydropropyl laurylglucoside.
7 . The formulation of claim 1 wherein the one or more alkyldimonium hydroxypropyl alkylglucoside includes stearyldimonium hydropropyl decylglucoside.
8 . The formulation of claim 1 further comprising poly(hexamethylene biguanide) at a concentration form 0.05 ppm to 0.5 ppm.
9 . The formulation of claim 1 wherein the pharmaceutical active is prescribed by or recommended by a physician, or a health care provider, to treat an ocular condition or an ocular disease.
10 . The formulation of claim 1 wherein the ocular condition is dry eye.
11 . The formulation of claim 1 wherein the pharmaceutical active is prescribed by or recommended by a physician, or a health care provider, to treat a dermatological condition or a dermatological disease.
12 . The formulation of claim 1 wherein the pharmaceutical active is prescribed by or recommended by a physician, or a health care provider, to treat seasonal allergies.
13 . A formulation comprising one or more alkyldimonium hydroxypropyl alkylglucosides selected from the group consisting of stearyldimonium hydropropyl laurylglucoside, stearyldimonium hydropropyl decylglucoside and poly(lauryldimonium hydroxypropyl laurylglucosides chloride, wherein the formulation is a pharmaceutical formulation for ophthalmic or nasal administration.
14 . The formulation of claim 13 wherein the total concentration of the one or more alkyldimonium hydroxypropyl alkylglucosides in the formulation is from 0.003% to 0.05% by weight.
15 . The formulation of claim 13 further comprising a pharmaceutical active that is effective for treating a patient diagnosed with an ocular disease selected from glaucoma, diabetic retinopathy, diabetic macular edema, cystoid macular edema, age macular degeneration, optic neuritis, retinitis, chorioretinitis, intermediate and posterior uveitis and choroidal neovascuralization
16 . The formulation of claim 13 further comprising a pharmaceutical active that is effective for treating a patient with an ocular allergic condition or inflammation of the eye.